Lymphocytic Leukemia, Acute Clinical Trials

A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
Novel neural circuit biomarkers of major depression response to computer-augmented CBT (1R01MH110939 - 01A1)

MDD subjects will be scheduled to receive CCBT at the first available appointment; all will be scheduled within 4 weeks. All subjects will have an fMRI at baseline; MDD subjects will have an fMRI after treatment. MDD subjects scheduled to start CCBT treatment after 3 weeks will complete an additional …

  • 0 views
  • 19 Feb, 2024
  • 1 location
AN UN-BLINDED INTRA-PATIENT COMPARISON OF TRANSBRONCHIAL FORCEPS BIOPSY AND CRYOBIOPSY FOR PERIPHERAL PULMONARY LESIONS

Both tools are currently available but have not been adequately compared. All patients will undergo both biopsy types and the success of providing a diagnosis will be compared.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab

If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, and blood draws.

  • 0 views
  • 19 Feb, 2024
  • 1 location
PRELIMINARY STUDY OF OPTICAL BIOMARKERS FOR NEURODEGENERATION IN CHRONIC CEREBROVASCULAR DISEASE

We will be recruiting 60 subjects in total: 30 healthy, 15 with known narrowing of the carotid artery, and 15 small vessel stroke. All subjects will undergo at least 1 optical blood flow monitoring session, and the non-healthy subjects will undergo an additional MRI.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Bone Water and Mineralization Measured by Nuclear Magnetic Resonance

Labs will be done at the screening visit and at the 12 month visit to ensure that subjects are healthy to receive infusion. All study participants will receive 1200 mg of calcium and 1000 units of Vitamin D. DXA, pQCT and MRI will be repeated at 12 and 24 months.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease

Up to 18 subjects will be enrolled; interim analyses will be conducted after first 6 and next 6 to assess dosage of CT1812 and to determine if there is sufficient evidence of oligomer displacement to continue full trial with all 18 subjects.

  • 0 views
  • 19 Feb, 2024
  • 1 location
TapToSleep: Guided Behavioral Approaches for Insomnia in Older Adults

 The purpose of this study is to examine the effects of this smartphone-delivered behavioral treatment for insomnia in older adults. This is a remote telehealth study, which means that all study procedures are conducted online and/or by phone.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular Reactivity

Each participant, from both cohorts, will undergo 2 MRIs and 2 blood draws, per visit. All participants will be compensated for time taken to participate in the study. Key eligibility criteria include men and women, ages 18-35 with a BMI of 18.5-30.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, …

  • 0 views
  • 19 Feb, 2024
  • 1 location